Tin tức & Cập nhật

Periconception parental vitamin B12 and postconception maternal red blood cell (RBC) folate are predictive of lower birth defect prevalence, suggests a study.

Arginine therapy is no better than placebo in terms of improving outcomes in children and young adults with sickle cell disease (SCD) who are experiencing acute pain episodes, according to the phase III STArT trial.

Measurements of rituximab serum concentration are predictive of future drug concentrations associated with early B-cell repopulation in children with inflammatory diseases, suggests a study.

A combined intrahepatic (IH) and periduodenal (PD) embolization strategy results in higher initial response rates and longer duration of remission compared with IH embolization alone in congenital heart disease (CHD) patients with protein-losing enteropathy (PLE), a study has shown.

Congenital toxoplasmosis, syphilis, rubella, cytomegalovirus, or herpes simplex (TORCH) infections are rare but are associated with intellectual disability and autism, as shown in a study.

A positive association exists between early pregnancy metabolomic signatures and child growth acceleration, a study has shown.

Problematic digital media use is associated with increased risks of mental health issues, self-harm or suicidal ideation, sleep problems, and substance use in adolescents. Physical-health outcomes, including obesity, myopia, and cardiometabolic risk, have been reported across all ages spanning childhood to adolescence. Thirteen global experts called for immediate public health action worldwide in a series of three papers published in The Lancet.

In children with Kawasaki disease, coronary artery dilation at diagnosis and age below 6 months predict coronary artery aneurysm across Japanese and US cohorts.

Dupilumab appears to be effective and safe in the long-term treatment of children with atopic dermatitis (AD) in the clinical setting, according to a multicentre, prospective cohort study.

New drug applications approved by US FDA as of 16-31 August 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.